Task Order (Under BARDA MCM-CSN Contract): Panblok H7 Influenza Vaccine at Three Dose Levels Adjuvanted with AS03 or MF59 Vaccine Trial (Phase 2)

Sponsor: Department of Health and Human Services (HHS)/Office of the Assistant Secretary for Preparedness and Response (ASPR)/Biomedical Advanced Research and Development Authority (BARDA)

Disease: Since 2013, influenza A (H7N9) has caused annual epidemics in China and has infected over 1500 people (as of 26 March 2020, per the World Health Organization). Data from the first four H7N9 epidemics in China shows a mortality rate of approximately 40%.

Objective: Although there has been limited human-to-human transmission, the CDC Influenza Risk Assessment Tool rated this virus as having the greatest potential to cause a pandemic and as potentially posing the greatest risk to severely impact public health. This study was conducted to prepare for the potential spread of H7N9 virus to the United States.

Period of involvement: May 2017 – September 2019

Services: Rho provided full-service support for this clinical trial. Additionally, BARDA awarded Rho a related Influenza vaccine trial in the Fall of 2019.